120 related articles for article (PubMed ID: 25439683)
21. The efficacy and safety of bevacizumab combined with chemotherapy in treatment of HER2-negative metastatic breast cancer: a meta-analysis based on published phase III trials.
Fang Y; Qu X; Cheng B; Chen Y; Wang Z; Chen F; Xiong B
Tumour Biol; 2015 Mar; 36(3):1933-41. PubMed ID: 25387808
[TBL] [Abstract][Full Text] [Related]
22. Bevacizumab in advanced colorectal cancer: a challenge to the current paradigm.
Booth C
J Clin Oncol; 2008 Oct; 26(28):4693-4; author reply 4694-5. PubMed ID: 18824719
[No Abstract] [Full Text] [Related]
23. Bevacizumab in the treatment of metastatic breast cancer: three case reports.
Ferreira A; Vieira C; Rodrigues A; Pereira D; Rodrigues H; Dávila C; Bento S
Curr Opin Oncol; 2011 Apr; 23 Suppl():S11-9. PubMed ID: 21490480
[TBL] [Abstract][Full Text] [Related]
24. Lapatinib plus capecitabine in patients with HER2-positive advanced breast cancer.
Cameron D
Clin Adv Hematol Oncol; 2007 Jun; 5(6):456-8. PubMed ID: 17679920
[No Abstract] [Full Text] [Related]
25. Increased mean corpuscular volume of red blood cells predicts response to metronomic capecitabine and cyclophosphamide in combination with bevacizumab.
Dellapasqua S; Bagnardi V; Bertolini F; Sandri MT; Pastrello D; Cancello G; Montagna E; Balduzzi A; Mancuso P; Luini A; Goldhirsch A; Colleoni M
Breast; 2012 Jun; 21(3):309-13. PubMed ID: 22341133
[TBL] [Abstract][Full Text] [Related]
26. Capecitabine and trastuzumab in heavily pretreated metastatic breast cancer.
Bartsch R; Wenzel C; Altorjai G; Pluschnig U; Rudas M; Mader RM; Gnant M; Zielinski CC; Steger GG
J Clin Oncol; 2007 Sep; 25(25):3853-8. PubMed ID: 17679724
[TBL] [Abstract][Full Text] [Related]
27. Capecitabine and docetaxel combination for the treatment of breast cancer.
Morishita M; Leonard RC
Womens Health (Lond); 2008 Jan; 4():11-22. PubMed ID: 19072447
[TBL] [Abstract][Full Text] [Related]
28. Metronomic chemotherapy combined with bevacizumab and erlotinib in patients with metastatic HER2-negative breast cancer: clinical and biological activity.
Montagna E; Cancello G; Bagnardi V; Pastrello D; Dellapasqua S; Perri G; Viale G; Veronesi P; Luini A; Intra M; Calleri A; Rampinelli C; Goldhirsch A; Bertolini F; Colleoni M
Clin Breast Cancer; 2012 Jun; 12(3):207-14. PubMed ID: 22520733
[TBL] [Abstract][Full Text] [Related]
29. New treatment strategies provide more options for patients with breast cancer.
Hampton T
JAMA; 2008 Jul; 300(4):381-2. PubMed ID: 18647973
[No Abstract] [Full Text] [Related]
30. A phase II study of trastuzumab emtansine in patients with human epidermal growth factor receptor 2-positive metastatic breast cancer who were previously treated with trastuzumab, lapatinib, an anthracycline, a taxane, and capecitabine.
Krop IE; LoRusso P; Miller KD; Modi S; Yardley D; Rodriguez G; Guardino E; Lu M; Zheng M; Girish S; Amler L; Winer EP; Rugo HS
J Clin Oncol; 2012 Sep; 30(26):3234-41. PubMed ID: 22649126
[TBL] [Abstract][Full Text] [Related]
31. Safety results from a phase III study (TURANDOT trial by CECOG) of first-line bevacizumab in combination with capecitabine or paclitaxel for HER-2-negative locally recurrent or metastatic breast cancer.
Lang I; Inbar MJ; Kahán Z; Greil R; Beslija S; Stemmer SM; Kaufman B; Zvirbule Z; Steger GG; Messinger D; Brodowicz T; Zielinski C
Eur J Cancer; 2012 Nov; 48(17):3140-9. PubMed ID: 22640829
[TBL] [Abstract][Full Text] [Related]
32. [Efficacy of docetaxel combined capecitabine on metastatic breast cancer].
Wang XX; Zhou ZM; Yuan ZY; Zhang DS; Shi YX; Jiang WQ
Ai Zheng; 2007 Apr; 26(4):407-10. PubMed ID: 17430662
[TBL] [Abstract][Full Text] [Related]
33. Novel regimens of capecitabine alone and combined with irinotecan and bevacizumab in colorectal cancer xenografts.
Kolinsky K; Zhang YE; Dugan U; Heimbrook D; Packman K; Higgins B
Anticancer Res; 2009 Jan; 29(1):91-8. PubMed ID: 19331137
[TBL] [Abstract][Full Text] [Related]
34. Efficacy and safety of bevacizumab-based combination regimens in patients with previously untreated metastatic colorectal cancer: final results from a randomised phase II study of bevacizumab plus 5-fluorouracil, leucovorin plus irinotecan versus bevacizumab plus capecitabine plus irinotecan (FNCLCC ACCORD 13/0503 study).
Ducreux M; Adenis A; Pignon JP; François E; Chauffert B; Ichanté JL; Boucher E; Ychou M; Pierga JY; Montoto-Grillot C; Conroy T
Eur J Cancer; 2013 Apr; 49(6):1236-45. PubMed ID: 23352604
[TBL] [Abstract][Full Text] [Related]
35. Paclitaxel and bevacizumab with or without capecitabine as first-line treatment for HER2-negative locally recurrent or metastatic breast cancer: a multicentre, open-label, randomised phase 2 trial.
Lam SW; de Groot SM; Honkoop AH; Jager A; ten Tije AJ; Bos MM; Linn SC; van den Bosch J; Kroep JR; Braun JJ; van Tinteren H; Boven E;
Eur J Cancer; 2014 Dec; 50(18):3077-88. PubMed ID: 25459393
[TBL] [Abstract][Full Text] [Related]
36. Randomized phase III trial of capecitabine compared with bevacizumab plus capecitabine in patients with previously treated metastatic breast cancer.
Miller KD; Chap LI; Holmes FA; Cobleigh MA; Marcom PK; Fehrenbacher L; Dickler M; Overmoyer BA; Reimann JD; Sing AP; Langmuir V; Rugo HS
J Clin Oncol; 2005 Feb; 23(4):792-9. PubMed ID: 15681523
[TBL] [Abstract][Full Text] [Related]
37. [Combination therapy herceptin+xeloda].
Schaller G
Onkologie; 2002 Dec; 25 Suppl 5():17-8; discussion 19. PubMed ID: 23573615
[No Abstract] [Full Text] [Related]
38. TP53 genomics predict higher clinical and pathologic tumor response in operable early-stage breast cancer treated with docetaxel-capecitabine ± trastuzumab.
Glück S; Ross JS; Royce M; McKenna EF; Perou CM; Avisar E; Wu L
Breast Cancer Res Treat; 2012 Apr; 132(3):781-91. PubMed ID: 21373875
[TBL] [Abstract][Full Text] [Related]
39. Neoadjuvant oxaliplatin and capecitabine and bevacizumab without radiotherapy for poor-risk rectal cancer: N-SOG 03 Phase II trial.
Uehara K; Hiramatsu K; Maeda A; Sakamoto E; Inoue M; Kobayashi S; Tojima Y; Yoshioka Y; Nakayama G; Yatsuya H; Ohmiya N; Goto H; Nagino M
Jpn J Clin Oncol; 2013 Oct; 43(10):964-71. PubMed ID: 23935207
[TBL] [Abstract][Full Text] [Related]
40. Trastuzumab emtansine in breast cancer.
Dirix LY; Rutten A; Huget P; Dirix M
Expert Opin Biol Ther; 2013 Apr; 13(4):607-14. PubMed ID: 23477731
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
